CaroGen Overview

  • Founded
  • 2012
Founded
  • Status
  • Private
  • Employees
  • 8
Employees
  • Latest Deal Type
  • Grant
  • Latest Deal Amount
  • $1.4M
Latest Deal Amount
  • Investors
  • 6

CaroGen General Information

Description

Provider of VLV platform intended for infectious diseases and cancer. The company's platform is safe and has a large capacity to deliver the genes for multiple types of warhead proteins including antigens, cytokines and other peptides and functional RNA molecules, such as shRNA, enabling healthcare providers to maximize the efficacy of immunotherapy.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Primary Office
  • 400 Farmington Avenue
  • Cell & Genome Sciences Building R2802
  • Farmington, CT 06032
  • United States
+1 (203) 000-0000

CaroGen Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

CaroGen Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Grant 01-Apr-2019 $1.4M 00.000 Completed Pre-Clinical Trials
3. Grant 18-Jun-2018 00000 00.000 Completed Pre-Clinical Trials
2. Early Stage VC (Series A) 11-Oct-2016 $2.82M $2.82M 000.00 Completed Pre-Clinical Trials
1. Grant 03-Apr-2014 $10K Completed Startup
To view CaroGen’s complete valuation and funding history, request access »

CaroGen Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 0,000,000 00.000000 00 00.00 00.00 00 00.00 000
To view CaroGen’s complete cap table history, request access »

CaroGen Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Provider of VLV platform intended for infectious diseases and cancer. The company's platform is safe and has a large cap
Drug Discovery
Farmington, CT
8 As of 2021
00.000
0000000000 00.000

00000000

lore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliqui
000000000000000
Sunnyvale, CA
0 As of 0000
00.000
0000000000 00.000

000000

in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat n
0000 000000000
Paris, France
00 As of 0000
000.00
000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

CaroGen Competitors (21)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Altravax Venture Capital-Backed Sunnyvale, CA 0 00.000 0000000000 00.000
000000 Corporation Paris, France 00 000.00 000000000 000.00
00000000000 Formerly VC-backed Louisville, CO 0 00000 000000&0 00000
000000 Venture Capital-Backed San Diego, CA 0 00.000 0000000000 0 00.000
000000000 Corporation Illkirch-Graffenstaden, France 000 00000 000000000 00000
You’re viewing 5 of 21 competitors. Get the full list »

CaroGen Executive Team (7)

Name Title Board Seat Contact Info
Bijan Almassian Ph.D Co-Founder, President, Chief Executive Officer & Co-Chairman
Michael Robek Ph.D Co-Founder & Member of Scientific Advisory Board
Joseph Rininger Ph.D Vice President, Product Development & Project Management
Valerain Nakaar Ph.D Co-Founder, Vice President, Research & Development & Board Member
Stephen Mason Vice President of Discovery
You’re viewing 5 of 7 executive team members. Get the full list »

CaroGen Board Members (9)

Name Representing Role Since
Fengyou Lu Self Board Member 000 0000
Frank Marco JD Wiggin and Dana Board Member 000 0000
Harry Penner Jr. Self Co-Chairman 000 0000
John Rose Ph.D CaroGen Co-Founder & Chairman of Scientific Advisory Board 000 0000
Michael Robek Ph.D CaroGen Co-Founder & Member of Scientific Advisory Board 000 0000
You’re viewing 5 of 9 board members. Get the full list »

CaroGen Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

CaroGen Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
National Institutes of Health Government 000 0000 000000 0
U.S. Department of Health and Human Services Government Minority 000 0000 000000 0
The National Institute of Diabetes and Digestive and Kidney Diseases Government 000 0000 000000 0
Connecticut Innovations Venture Capital Minority 000 0000 000000 0
GP Fortune Investment Partners Other Minority 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »

CaroGen Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000 00000000000 10-Oct-2013 0000 00000 00000 Drug Discovery
To view CaroGen’s complete investments history, request access »